SSI Diagnostica Group, a prominent player in infectious disease testing solutions, has taken a significant step forward in its growth strategy by acquiring InDevR, a Colorado-based innovator in multiplexing technology for vaccine testing and quality control. This acquisition enhances SSI Diagnostica’s position in the market, particularly in the area of pneumococcal vaccine quality control (QC), by integrating advanced multiplexing assays and customization options. With InDevR’s established expertise in influenza and mRNA vaccine QC, SSI Diagnostica is poised to broaden its offerings and address the evolving challenges faced by vaccine developers.
Strategic Expansion in Vaccine Development
The acquisition of InDevR is a natural progression in SSI Diagnostica’s mergers and acquisitions strategy aimed at expanding its global reach and enhancing its product portfolio. The company operates through two main divisions: Life Science and In Vitro Diagnostics, focusing on three core application areas: vaccine development, disease surveillance, and diagnostic testing. This strategic alignment not only complements SSI Diagnostica’s existing capabilities but also reinforces its commitment to addressing the complex landscape of vaccine development.
Earlier in 2025, SSI Diagnostica expanded its In Vitro Diagnostics capabilities by acquiring Gulf Coast Scientific, which allowed it to enhance its testing portfolio for Helicobacter pylori. The integration of InDevR’s multiplexing expertise marks a pivotal moment for the Life Science Solutions segment, enabling SSI Diagnostica to tackle the increasingly intricate challenges posed by emerging disease variants and the demand for more efficient multiplexing solutions.
Meeting the Needs of Vaccine Developers
Christina Lindved, CEO of SSI Diagnostica Group, emphasized the importance of this acquisition in meeting the needs of vaccine developers. As the landscape of infectious diseases continues to evolve, the ability to perform multiplexed assays is becoming increasingly critical. By merging SSI Diagnostica’s leadership in vaccine testing with InDevR’s innovative closed multiplexing system, the company aims to empower its customers to scale their operations effectively and future-proof their vaccine pipelines.
Kathy Rowlen, CEO of InDevR, highlighted the alignment between the two companies from the onset of discussions. She expressed confidence that joining forces with SSI Diagnostica will amplify their impact in the global biopharma sector, ultimately delivering a more comprehensive portfolio to the vaccine and surveillance markets.
Commitment to End-to-End Solutions
InDevR’s advanced multiplexing technology fits seamlessly into SSI Diagnostica’s vision of providing end-to-end solutions across both Life Science and In Vitro Diagnostics. Nachum (Homi) Shamir, Chairman of SSI Diagnostica Group, reiterated the company’s commitment to growth through both organic expansion and targeted acquisitions. By integrating InDevR’s capabilities, SSI Diagnostica is better equipped to meet the evolving demands of its customers, fulfilling its mission to empower healthcare professionals in the prevention, monitoring, and diagnosis of infectious diseases.
Enhancing Quality Control for Vaccines
The addition of InDevR’s technologies not only strengthens SSI Diagnostica’s portfolio but also enhances its capabilities in quality control for vaccines. The VaxArray® portfolio and the CypherOne system, which facilitate digital imaging and automated interpretation of hemagglutination assays, represent significant advancements that will support the rigorous testing processes necessary for vaccine development. As the market increasingly prioritizes quality and efficiency, this acquisition positions SSI Diagnostica as a leader in the field of vaccine QC.
Global Footprint and Expertise
SSI Diagnostica Group employs approximately 600 individuals and maintains a presence in Denmark, the United States, and China. This international footprint enables the company to stay close to its customers and patients across all continents, ensuring responsiveness to market needs. The integration of InDevR’s expertise will further enhance this global approach, allowing for a more robust reaction to the diverse challenges faced in vaccine development and testing.
Conclusion
The acquisition of InDevR by SSI Diagnostica Group marks a strategic move to enhance its capabilities in vaccine development and quality control. By leveraging InDevR’s advanced multiplexing technologies, SSI Diagnostica is well-positioned to address the complexities of the modern vaccine landscape. This acquisition not only strengthens the company’s portfolio but also underscores its commitment to empowering healthcare professionals in their quest to combat infectious diseases effectively.
- Key Takeaways:
- SSI Diagnostica Group acquires InDevR to boost vaccine QC capabilities.
- The acquisition enhances SSI’s portfolio in Life Science and In Vitro Diagnostics.
- InDevR’s technology aligns with SSI’s mission to provide comprehensive solutions in vaccine development.
- The move is part of SSI’s broader strategy to enhance its global presence and expertise.
Read more → www.cincinnati.com